.svg)
Sometimes the most interesting conversations at startup events happen when things don’t go exactly as planned.
A spring snowstorm rolled through Boulder during Boulder Startup Week, forcing venue changes and reshuffling session formats. What emerged from one healthcare founder workshop was something unexpectedly valuable: smaller, more candid conversations between founders, operators, and investors wrestling with questions that rarely get discussed openly in early-stage company building.
Each year, Boulder Startup Week brings together founders, operators, investors, and ecosystem leaders for a week of candid conversations spanning startups, healthcare, AI, and entrepreneurship. The best sessions often feel less like presentations and more like real-time problem solving among people actively building.
The session centered on a deceptively simple prompt:
Are you building a product… or a company?
At first glance, the distinction may seem semantic. In practice, it shapes nearly every decision a founder makes: hiring, fundraising, infrastructure, go-to-market strategy, timelines, and even how success itself is defined.
The conversation challenged one of the startup ecosystem’s default assumptions: that every meaningful product should become a venture-scale company.
In healthcare, especially, reality is often more nuanced.
Some products are best positioned to scale independently. Others may create the most value through acquisition, integration, or licensing models. None of those outcomes are inherently less ambitious. In many cases, they may actually represent the more strategically disciplined path.
What made the discussion especially timely was the backdrop of AI.
Founders today can build and operationalize products with dramatically leaner infrastructure than even a few years ago. Capabilities that once required large teams, extensive technical resources, or entire operational departments can increasingly be handled by small, focused teams using modern tooling.
That shift raises an important question:
What actually needs to become a company now?
As the breakout conversations unfolded, several themes surfaced repeatedly.
One was the danger of false signals.
In healthcare, early traction can be deceptively encouraging. A successful pilot, positive customer conversations, or early enthusiasm do not automatically translate into durable demand. Many founders discover too late that interest and repeatable market pull are not the same thing.
The gap between initial enthusiasm and repeatable customer behavior is where many startups stall.
Another recurring theme was that solving distribution and incentive alignment is often harder than building the technology itself.
A product can solve a legitimate problem and still struggle commercially if it does not align with how customers make decisions, experience value, or change behavior. Especially in healthcare, founders are often navigating emotionally-charged problems, fragmented and distorted markets, and deeply ingrained habits all at once.
One breakout led by Stand Together Ventures Lab investor Amina Resheidat focused on how founders identify real market signals early enough to shape product evolution before overbuilding around assumptions.
Rather than relying solely on high-level strategy conversations, she encouraged founders to pay close attention to the people closest to the customer experience. In one example, she described how customer success leaders can become an important “voice of the customer” inside an organization, surfacing recurring friction points, unmet needs, and patterns leadership teams may not immediately see.
It was a subtle but powerful reminder:
The clearest market signals are often human before they become measurable.
That idea resonated deeply throughout the broader workshop discussion.
The conversation was not anti-growth, anti-venture, or anti-ambition. If anything, it encouraged founders to pursue clarity earlier and with greater honesty.
Too often, founders feel pressure to prematurely optimize for “company-building” before fully understanding the type of signal the market is actually giving them. Teams get hired. Infrastructure gets layered in. Capital strategies expand.
And in some cases, the core assumptions remain only partially validated.
One of the most refreshing aspects of the session was how openly participants discussed pivoting, iteration, and changing direction. These moments were not framed as failure. They were framed as disciplined learning.
That mindset feels increasingly important as AI reshapes what small teams can accomplish and lowers the operational barriers required to create meaningful products.
Not every valuable product needs to become a venture-scale company. In many cases, clarity that a founder is building a product rather than a company can be an enormous strategic advantage.
But the conversation also surfaced an important distinction.
In healthcare, a great deal of capital flows toward solutions that are either disruptive enough to be captured and killed, or narrow enough to roll up into a platform of existing point solutions.
At STVL, we are particularly drawn to founders pursuing something different: building experiences so superior for consumers that they fundamentally reshape expectations, behaviors, and markets rather than simply operating within the confines of existing systems.
That kind of transformation is significantly harder.
But when it works, it has the potential to change industries entirely.
